Patents by Inventor John Arnold Werner

John Arnold Werner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ?3 adrenergic agonists
    Patent number: 7208505
    Abstract: The present invention relates to a ?3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful, e.g.
    Type: Grant
    Filed: August 6, 2002
    Date of Patent: April 24, 2007
    Assignee: Eli Lilly and Company
    Inventors: Daniel Jon Sall, Jolie Anne Bastian, Rushad Eruch Karanjawala, Cynthia Darshini Jesudason, Theo Schotten, Britta Evers, Gerd Reuhter, Don Richard Finley, Freddie Craig Stevens, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, John Xiaoqiang He, John Arnold Werner, William George Trankle, Andrew Michael Ratz
  • 3-Substituted oxindole ?agonsists
    Patent number: 7122680
    Abstract: The present invention relates to a ?3 adrenergic receptor agonist of formula I: or a pharmaceutical salt thereof; which is useful for treating Type II diabetes and/or obesity.
    Type: Grant
    Filed: October 21, 2004
    Date of Patent: October 17, 2006
    Assignee: Eli Lilly and Company
    Inventors: Cynthia Darshini Jesudason, Daniel Jon Sall, Freddie Craig Stevens, John Arnold Werner
  • 3-substituted oxindole ?3 agonists
    Patent number: 7087635
    Abstract: The present invention relates to a ?3 adrenergic receptor agonist of formula I: or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.
    Type: Grant
    Filed: March 16, 2005
    Date of Patent: August 8, 2006
    Assignee: Eli Lilly and Company
    Inventors: Daniel Jon Sall, Jolie Anne Bastian, Cynthia Darshini Jesudason, Don Richard Finley, Freddie Craig Stevens, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, John Xiaoqiang He, John Arnold Werner, William George Trankle, Andrew Michael Ratz, Theo Schotten, Gerd Reuhter
  • 3-substituted oxindole ?-3 agonists
    Patent number: 6911463
    Abstract: The present invention relates to a ?3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.
    Type: Grant
    Filed: August 6, 2002
    Date of Patent: June 28, 2005
    Assignee: Eli Lilly and Company
    Inventors: Daniel Jon Sall, Jolie Anne Bastian, Cynthia Darshini Jesudason, Theo Schotten, Gerd Reuhter, Don Richard Finley, Freddie Craig Stevens, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, John Xiaoqiang He, John Arnold Werner, William George Trankle, Andrew Michael Ratz
  • 3-substituted oxindole beta-3 agonists
    Publication number: 20040242668
    Abstract: The present invention relates to a &bgr;3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.
    Type: Application
    Filed: February 11, 2004
    Publication date: December 2, 2004
    Inventors: Daniel Jon Sall, Jolie Anne Bastian, Cynthia Darshini Jesudason, Theo Schotten, Gerd Reuhter, Don Richard Finley, Freddie Craig Stevens, Vincent Patrick Rocco, Patrick Gianpietro Spinazze, John Xiaoqiang He, John Arnold Werner, William George Trankle, Andrew Michael Ratz
  • Beta3 adrenergic agonists
    Publication number: 20040242633
    Abstract: The present invention relates to a &bgr;3 adrenergic receptor agonist of formula I: 1
    Type: Application
    Filed: May 4, 2004
    Publication date: December 2, 2004
    Inventors: Britta Evers, Cynthia Darshini Jesudason, Rushad Eruch Karanjawala, David Michael Remick, Gerd Ruehter, Daniel Jon Sall, Theo Schotten, Miles Goodman Siegel, Wolfgang Stenzel, Russell Dean Stucky, John Arnold Werner
  • 3-Substituted oxindole &bgr; 3 agonists
    Patent number: 6825220
    Abstract: The present invention relates to a &bgr;;3 adrenergic receptor agonist of formula I: (1); or a pharmaceutical salt thereof; which is useful for treating Type II diabetes and/or obesity.
    Type: Grant
    Filed: April 11, 2003
    Date of Patent: November 30, 2004
    Assignee: Eli Lilly and Company
    Inventors: Cynthia Darshini Jesudason, Daniel Jon Sall, Freddie Craig Stevens, John Arnold Werner
  • 3-Substituted oxindole beta 3 agonists
    Publication number: 20040097532
    Abstract: The present invention relates to a &bgr;;3 adrenergic receptor agonist of formula I: (I); or a pharmaceutical salt thereof; which is useful for treating Type II diabetes and/or obesity.
    Type: Application
    Filed: April 11, 2003
    Publication date: May 20, 2004
    Inventors: Cynthia Darshini Jesudason, Daniel Jon Sall, Freddie Craig Stevens, John Arnold Werner
  • &bgr;3 adrenergic agonists
    Patent number: 6730792
    Abstract: The present invention relates to a &bgr;3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof, which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type II diabetes and/or obesity. The compound can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compound can be used to reduced neurogenic inflammation or as an antidepressant agent. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for decreasing gut motility are also disclosed.
    Type: Grant
    Filed: December 13, 2002
    Date of Patent: May 4, 2004
    Assignee: Eli Lilly and Company
    Inventors: Britta Evers, Cynthia Darshini Jesudason, Rushad Eruch Karanjawala, David Michael Remick, Daniel Jon Sall, Miles Goodman Siegel, Wolfgang Stenzel, Russell Dean Stucky, John Arnold Werner
  • Beta3 adrenergic agonists
    Publication number: 20030191156
    Abstract: The present invention relates to a &bgr;3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof, which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type II diabetes and/or obesity. The compound can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compound can be used to reduced neurogenic inflammation or as an antidepressant agent. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for decreasing gut motility are also disclosed.
    Type: Application
    Filed: December 13, 2002
    Publication date: October 9, 2003
    Inventors: Britta Evers, Cynthia Darshini Jesudason, Rushad Eruch Karanjawala, David Michael Remick, Daniel Jon Sall, Miles Goodman Siegel, Wolfgang Stenzel, Russell Dean Stucky, John Arnold Werner
  • Processes and intermediates useful to make antifolates
    Patent number: 6426417
    Abstract: The present invention concerns intermediates, and processes directed to and from those intermediates, to a series of pyrimidine derivatives of formula (V), which are intermediates to useful antifolate compounds or are themselves useful antifolate compounds.
    Type: Grant
    Filed: August 2, 2000
    Date of Patent: July 30, 2002
    Assignee: Eli Lilly and Company
    Inventors: Charles Jackson Barnett, Steven Eugene Dunlap, Michael Edward Kobierski, John Arnold Werner
  • Anti-viral compounds
    Patent number: 6114327
    Abstract: The present application provides a series of benzimidazole compounds of formula I: ##STR1## which inhibit the growth of picornaviruses, such as rhinoviruses (bovine and human), enteroviruses such as polioviruses, coxsackieviruses of the A and B groups, or echo virus, cardioviruses such as encephalomyocarditis (EMC), apthoviruses such as foot and mouth disease virus, and flaviviruses such as hepatitis C virus and bovine viral diarrhea virus.Such compounds are also useful as intermediates for preparing additional benzimidazole antiviral compounds.
    Type: Grant
    Filed: October 22, 1999
    Date of Patent: September 5, 2000
    Assignee: Eli Lilly and Company
    Inventors: Steven Eugene Dunlap, Louis Nickolaus Jungheim, Mark Joseph Tebbe, Gilbert Thomas Voy, John Arnold Werner